SG11201703298SA - Activated bifidobacteria and methods of use thereof - Google Patents

Activated bifidobacteria and methods of use thereof

Info

Publication number
SG11201703298SA
SG11201703298SA SG11201703298SA SG11201703298SA SG11201703298SA SG 11201703298S A SG11201703298S A SG 11201703298SA SG 11201703298S A SG11201703298S A SG 11201703298SA SG 11201703298S A SG11201703298S A SG 11201703298SA SG 11201703298S A SG11201703298S A SG 11201703298SA
Authority
SG
Singapore
Prior art keywords
methods
activated bifidobacteria
bifidobacteria
activated
Prior art date
Application number
SG11201703298SA
Inventor
David Kyle
David Mills
Samara Freeman-Sharkey
Original Assignee
Evolve Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55761664&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201703298S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evolve Biosystems Inc filed Critical Evolve Biosystems Inc
Publication of SG11201703298SA publication Critical patent/SG11201703298SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/529Infantis
SG11201703298SA 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof SG11201703298SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068553P 2014-10-24 2014-10-24
US201562133243P 2015-03-13 2015-03-13
PCT/US2015/057226 WO2016065324A1 (en) 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201703298SA true SG11201703298SA (en) 2017-05-30

Family

ID=55761664

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202002593SA SG10202002593SA (en) 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof
SG11201703298SA SG11201703298SA (en) 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202002593SA SG10202002593SA (en) 2014-10-24 2015-10-23 Activated bifidobacteria and methods of use thereof

Country Status (10)

Country Link
US (2) US10716816B2 (en)
EP (1) EP3209308B1 (en)
CN (2) CN114376234A (en)
AU (2) AU2015335601A1 (en)
BR (1) BR112017008284A8 (en)
CA (1) CA2965663C (en)
DK (1) DK3209308T3 (en)
MX (1) MX2017005260A (en)
SG (2) SG10202002593SA (en)
WO (1) WO2016065324A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2016065324A1 (en) 2014-10-24 2016-04-28 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
EP3212001A4 (en) 2014-10-31 2018-04-25 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
CN108138122B (en) 2014-12-23 2021-09-21 4D制药研究有限公司 Immune regulation
JP6427278B2 (en) 2014-12-23 2018-11-21 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited pirin polypeptide and immune modulation
RU2731067C2 (en) * 2015-03-05 2020-08-28 Сосьете Де Продюи Нестле С.А. Composition for use in improving stool consistence or frequency in infants or young children
SG10202002010VA (en) * 2015-03-13 2020-05-28 Evolve Biosystems Inc Compositions that metabolize or sequester free sugar monomers and uses thereof
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
HUE045413T2 (en) 2015-06-15 2019-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
DK3240554T3 (en) 2015-06-15 2019-10-28 4D Pharma Res Ltd BLAUTIA STERCOSIS AND WEXLERAE FOR USE IN TREATMENT OF INFLAMMATORY AND AUTO-IMMUNE DISEASES
SG10201912319SA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
NZ742787A (en) 2015-11-20 2020-02-28 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
ES2731579T3 (en) 2016-03-04 2019-11-18 4D Pharma Plc Compositions comprising bacterial blautia strains to treat visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018068261A2 (en) * 2016-03-11 2019-01-15 Evolve Biosystems Inc transient commensal microorganism to improve bowel health
US11318175B2 (en) * 2016-07-01 2022-05-03 Evolve Biosystems, Inc. Method for facilitating maturation of the mammalian immune system
TW201821093A (en) 2016-07-13 2018-06-16 英商4D製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
RS61872B1 (en) 2017-05-22 2021-06-30 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6978514B2 (en) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Composition containing bacterial strain
PT3638271T (en) 2017-06-14 2021-01-05 4D Pharma Res Ltd Compositions comprising bacterial strains
HRP20220747T1 (en) 2017-06-14 2022-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
CN107365705B (en) * 2017-07-14 2021-01-12 江苏微康生物科技有限公司 Freeze-drying protective agent for oil-soluble probiotic freeze-dried powder and application thereof
EP3675882A4 (en) 2017-08-30 2021-07-28 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
WO2019055718A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. Metabolomic revision of mammalian infants
WO2019143871A1 (en) 2018-01-17 2019-07-25 Evolve Biosystems, Inc. Activation of conditionally-expressed oligosaccharide pathways during fermentation of probiotic strains
SG11202011820VA (en) * 2018-05-30 2020-12-30 Evolve Biosystems Inc Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis
WO2019232513A1 (en) * 2018-06-01 2019-12-05 Evolve Biosystems, Inc. Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires
US20210161924A1 (en) * 2018-06-19 2021-06-03 Evolve Biosystems, Inc. Novel oligosaccharides for use in prebiotic applications
KR20220155595A (en) * 2020-03-20 2022-11-23 글리콤 에이/에스 Methods for providing solid HMO products, and solid HMO products obtained thereby
CN111826324A (en) * 2020-08-05 2020-10-27 厦门惠盈动物科技有限公司 Preparation method of lactobacillus rhamnosus powder
CN114568520A (en) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 Infant formula powder containing bifidobacterium longum subspecies infantis and application thereof
CN114568516A (en) * 2020-11-30 2022-06-03 内蒙古伊利实业集团股份有限公司 Composition containing bifidobacterium longum subsp. infantis and breast milk oligosaccharide and application thereof
CN116615203A (en) 2020-12-11 2023-08-18 帝斯曼知识产权资产管理有限公司 Improved prebiotic formulation
IT202100024911A1 (en) * 2021-09-29 2023-03-29 Univ Degli Studi Di Napoli Federico Ii Dipartimento Di Fisica Ettore Pancini PREBIOTIC BASED ON DELACTOSED "SCOTTA" FOR THE PREVENTION AND MANAGEMENT OF INTESTINAL DYSIBIOSIS

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
RU2180915C1 (en) 2001-04-28 2002-03-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского Consortium of bifidobacteria and lactobacilli used for preparing bacterial preparations, ferments for fermented-milk foodstuffs, fermented and nonfermented foodstuffs, biologically active supplements designated for correction of microflora in children in age below 3 years
ATE414428T1 (en) * 2003-10-24 2008-12-15 Nutricia Nv SYMBIOTIC COMPOSITION FOR SMALL CHILDREN
US20070082087A1 (en) * 2005-10-06 2007-04-12 Schweitzer Biotech Company Ltd. Fermented milk products containing bifidobacterium longum and isomalto oligosaccharide and the process for producing the same
EP1776877A1 (en) 2005-10-21 2007-04-25 N.V. Nutricia Method for stimulating the intestinal flora
US20110165127A1 (en) 2006-06-09 2011-07-07 Fabiola Masri Dairy-derived probiotic compositions and uses thereof
US8361756B2 (en) 2006-09-15 2013-01-29 The Regents Of The University Of California Bifidobacterial gene sequences and their use
US8197872B2 (en) 2007-05-17 2012-06-12 The Regents Of The University Of California Human milk oligosaccharides to promote growth of beneficial gut bacteria
WO2008153377A1 (en) * 2007-06-15 2008-12-18 N.V. Nutricia Nutrition with non-viable bifidobacterium and non-digestible oligosaccharide
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
UA32462U (en) 2008-02-14 2008-05-12 Харьковский Национальный Медицинский Университет Method for evaluation of effectiveness of correction of distortions of intestines microbiotsenosis in children of early age with atopic dermatitis
CA2658440C (en) * 2008-04-04 2016-08-23 Kraft Foods Global Brands Llc Dairy composition with probiotics and anti-microbial system
EP2143341A1 (en) 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
AU2009253281A1 (en) * 2008-05-27 2009-12-03 Nestec S.A. Probiotics to improve gut microbiota
PL2352389T3 (en) 2008-11-11 2016-07-29 Alimentary Health Ltd Bifidobacterium longum
EP2370084B1 (en) 2008-12-02 2014-10-22 Prolacta Bioscience, Inc. Human milk permeate compositions and methods of making and using same
US9649380B2 (en) 2009-01-12 2017-05-16 Pfizer Italia S.R.L. Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
US8198872B2 (en) 2009-03-10 2012-06-12 Honeywell International, Inc. Starter-generator with improved excitation
US7888062B1 (en) * 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
AU2011217614A1 (en) 2010-02-19 2012-08-02 Glycom A/S Production of 6'-O-sialyllactose and intermediates
US9200091B2 (en) * 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
EP2465509A1 (en) 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating acute respiratory tract infections
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2454948A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
CA2822660C (en) * 2010-12-31 2021-09-07 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides
WO2012107865A2 (en) * 2011-02-10 2012-08-16 Wyeth Llc Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
DK2814835T3 (en) 2012-02-14 2019-06-11 Univ California Enzymes and methods for cleaving N-glycans from glycoproteins
US10165788B2 (en) 2013-06-17 2019-01-01 The Regents Of The University Of California Methods and compositions for improved digestion of milk oligosaccharides
WO2016065324A1 (en) 2014-10-24 2016-04-28 Evolve Biosystems Inc. Activated bifidobacteria and methods of use thereof
WO2016094836A1 (en) 2014-12-12 2016-06-16 The Regents Of The University Of California Reduction of milk glycans and their degradation products in the neonate gut

Also Published As

Publication number Publication date
BR112017008284A8 (en) 2023-04-11
WO2016065324A1 (en) 2016-04-28
CA2965663C (en) 2023-04-04
BR112017008284A2 (en) 2017-12-19
CN114376234A (en) 2022-04-22
AU2015335601A1 (en) 2017-06-01
EP3209308A4 (en) 2018-06-27
US20200397837A1 (en) 2020-12-24
DK3209308T3 (en) 2022-10-03
US10716816B2 (en) 2020-07-21
CA2965663A1 (en) 2016-04-28
EP3209308A1 (en) 2017-08-30
CN107249611A (en) 2017-10-13
MX2017005260A (en) 2018-01-30
AU2021204822A1 (en) 2021-08-05
SG10202002593SA (en) 2020-05-28
EP3209308B1 (en) 2022-08-03
US20170304375A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
SG11201703298SA (en) Activated bifidobacteria and methods of use thereof
IL250415B (en) Anti-pdl- antibodies and methods of use thereof
HRP20210526T8 (en) Oxysterols and methods of use thereof
HK1255500A1 (en) Oxysterols and methods of use thereof
PL3160498T3 (en) Il-15-based molecules and methods of use thereof
GB201421847D0 (en) Dispensers and methods of use thereof
IL256531B (en) Oxysterols and methods of use thereof
GB201502084D0 (en) Catheter devices and related methods
IL251988A0 (en) Glycan-interacting compounds and methods of use
IL253234B (en) Methods of transdifferentiation and methods of use thereof
EP3157528A4 (en) Oxysterols and methods of use thereof
GB201417048D0 (en) Occupancy-control device and methods of use
GB201404470D0 (en) Therapeutic methods and materials
SI3089971T1 (en) Compounds and methods of use
SG11201704473WA (en) New methods and uses
EP3152281A4 (en) Defoaming agent and associated methods of use
ZA201703398B (en) Pharmaceutical composition and methods
HK1256368A1 (en) Calicheamicin-antibody-drug conjugates and methods of use
HK1243077A1 (en) Piperidinylpyrazolopyrimidinones and their use
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en) Compounds and their methods of use
IL248554A0 (en) Variants of dr3 and use thereof
GB2558547B (en) Actuatable paddle and methods of use
GB201509977D0 (en) Dispensers and methods of use thereof
GB201403697D0 (en) Compounds and methods of use